PLGA Nanoparticle Nanogel Delivery for Sustained AMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for age-related macular degeneration (AMD) suffer from a narrow therapeutic index, rapid drug clearance, frequent dose instillation, adverse effects, and poor therapeutic outcomes, necessitating a method for local delivery of anti-angiogenic agents like sunitinib to minimize dose frequency and enhance effectiveness.
Innovation Solution
Development of poly(lactic-co-glycolic acid) (PLGA)-based nanoparticles loaded with sunitinib, combined with a thermal reversible nanogel, for sustained drug delivery to the eye, providing a sustained release profile and reducing dosing frequency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic administration of anti-VEGF agents is used, then therapeutic coverage is broad, but therapeutic effectiveness is poor and clearance is rapid
Solution Approach 1:
The patent uses intravitreal injection as an intermediary delivery route to bypass systemic circulation and deliver anti-VEGF agents directly to the ocular site. This mediator approach overcomes the rapid clearance and poor effectiveness of systemic administration by placing the drug in close proximity to the target tissue, allowing sustained local action without relying on systemic distribution.
2Reliability
If frequent dose instillation is performed, then therapeutic effectiveness is maintained, but patient compliance decreases and adverse effects increase
Solution Approach 1:
The patent employs sustained-release formulations and ocular implant devices that pre-load therapeutic agents for prolonged delivery. This preliminary action stores the drug in a reservoir or matrix that releases it gradually over weeks or months, eliminating the need for frequent patient-administered doses while maintaining therapeutic effectiveness and improving compliance.
3Loss of time
If local delivery of sunitinib is implemented, then dosing frequency is reduced, but delivery precision must be increased
Solution Approach 1:
The patent applies local quality by designing ocular-specific delivery systems including intravitreal implants, ocular inserts, and targeted nanocarriers that concentrate sunitinib precisely at the retinal and choroidal sites. These systems ensure the drug is delivered exactly where needed in the eye with controlled release kinetics, reducing dosing frequency while maintaining high delivery precision through localized formulation design.
Data Source
AI summary
Disclosed are nanoparticles and nanogel drug compositions and the use thereof for treating age-related macular degeneration.